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ABSTRACT
Disrupting the interactions between human immun-
odeficiency virus type 1 (HIV-1) nucleocapsid (NC)
protein and structural elements of the packaging
signal (C-RNA) could constitute an ideal strategy to
inhibit the functions of this region of the genome lea-
der in the virus life cycle. We have employed electro-
spray ionization (ESI) Fourier transform mass
spectrometry (FTMS) to assess the ability of a series
of nucleic acid ligands to bind selected structures
of C-RNA and inhibit their specific interactions
with NC in vitro. We found that the majority of the
ligands included in the study were able to form stable
non-covalent complexes with stem–loop 2, 3 and 4
(SL2–4), consistent with their characteristic nucleic
acid binding modes. However, only aminoglycosidic
antibiotics were capable of dissociating preformed
NC SL3 and NC SL4 complexes, but not NC SL2.
The apparent specificity of these inhibitory effects
is closely dependent on distinctive structural fea-
tures of the different NC RNA complexes. The trends
observed for the IC50 values correlate very well with
thoseprovidedbytheligandbindingaffinitiesandthe
dissociation constants of target NC RNA complexes.
This systematic investigation of archetypical nucleic
acidligandsprovidesavalidframeworktosupportthe
design of novel ligand inhibitors for HIV-1 treatment.
INTRODUCTION
A primary cause of failure of the highly active anti-retroviral
therapy (HAART) used to control the infection of human
immunodeﬁciencyvirustype 1(HIV-1) isthe rapidemergence
of strains that are resistant to one or more of the active agents
used in typical multidrug regimens (1,2). Mutations of genes
coding for inhibitor targets, such as protease, reverse tran-
scriptase and gp41, result in a reduced response to treatment
from patients infected by resistant strains (3–5). The magni-
tude reached by the AIDS pandemic and the daunting problem
of drug resistance elevate the need for new therapeutic agents
with alternative mechanisms of action (6–8).
In the life cycle of HIV-1, the processes of genome recog-
nition, dimerization and packaging provide very attractive
opportunities for the development of novel anti-retroviral
strategies. These essential functions are mediated by the inter-
actions between the nucleocapsid (NC) domain of the Gag
polyprotein (9,10) and a highly conserved region of genomic
RNA, known as the packaging signal, or Y-RNA (11–13). The
structure of NC includes two zinc-ﬁnger motifs of retroviral
type (CCHC, Figure 1) (14,15), which are responsible for
its activity as a nucleic acid chaperone (16). Located in
the 50-untranslated region (50-UTR), the  120 nt comprising
Y-RNA have been shown to fold into relatively stable sec-
ondary structures identiﬁed as stem–loop 1 through 4 (SL1–4),
which serve as possible binding sites for NC during viral
replication (17–19). The characteristics and structural determ-
inants of these protein–RNA interactions have been extens-
ively investigated to elucidate the role played by the different
elements [reviewed in ref. (20)] and enable the identiﬁcation
of viable targets.
Different strategies have been proposed to disrupt the mech-
anism of genome recognition, dimerization and packaging by
targeting key structures involved in these processes. Based on
the observation that intact zinc-ﬁngers are crucial for NC
activity, different chemical agents have been investigated
for their ability to induce Zn
2+ ejection and protein deactiva-
tion (21–23). Peptides mimicking the 3D structure of NC,
which are intended to compete with the protein for its recog-
nition sites on genomic RNA, were either synthesized (24),
or isolated from phage-displayed libraries (25,26). Antisense
oligonucleotides were designed to hybridize with the palin-
dromic sequence of SL1 (27,28) and inhibit the inter-strand
base pairing that initiates genome dimerization (29–31).
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the packaging signal have revealed the ability of aminoglyc-
oside analogues to bind speciﬁc structures of Y-RNA in vitro
(32–35). The primary binding site was identiﬁed near the
dimerization initiation site on SL1, which is consistent with
the striking structural similarities between the dimeric form
of this stem–loop and the ribosomal aminoacyl-tRNA site
(A-site) of prokaryotes (34). However, depending on the
subtype sequence and experimental conditions employed for
the assays, binding was observed for both monomeric (32,33)
and dimeric forms of SL1 (34), thus casting doubt on the
ability of aminoglycosides to inhibit RNA dimerization.
In this report, we examine the interactions of a selection of
small molecule ligands with separate domains of the pack-
aging signal and their complexes with NC. Representative
members of different classes of nucleic acid binders (36–
38) were selected to sample archetypical structures that
may constitute valid templates for the development of new
anti-retroviral agents. Substrates included in the study consist
of RNA hairpins SL2 and SL3 (Figure 1), which are not
believed to be directly involved in genome dimerization,
but provide speciﬁc binding sites for NC during genome
recognition and packaging (17,18,20). In addition, a construct
corresponding to the putative SL4 has been investigated to
gain further insights into the mechanism of inhibition of NC–
RNA interactions in vitro, even though the possible participa-
tion of this sequence in long-range base pairing interactions
casts doubt on the actual existence of a discrete stem–loop
structure in vivo (39) and in full-length 50-UTR constructs
in vitro (40,41). An approach based on electrospray ionization
(ESI) (42,43) and Fourier transform mass spectrometry
(FTMS) (44,45) was followed to investigate ligand–RNA
interactions and evaluate the stability of NC-hairpin com-
plexes in the presence of ligands. The inherent low energy
involved with this ionization technique enables the observa-
tion of labile non-covalent complexes, which remain intact in
the gas-phase (46–48). This characteristic has led to the suc-
cessful investigation of protein–nucleic acid, nucleic acid–
nucleic acid and small ligand–nucleic acid interactions by
mass spectrometry [reviewed in ref. (49,50)]. In a recent
study, we employed ESI-FTMS to determine the stoichi-
ometry and binding afﬁnity of NC for SL2, SL3 and SL4 in
solution (51). We have now extended this approach to explore
possible inhibitory effects on NC-hairpin complexes in solu-
tion. The results are discussed in the context of the speciﬁc
structural features of substrates and ligands, in an effort to
understand the binding determinants and the possible implica-
tions for the development of new therapeutic strategies aimed
at interfering with the interactions of NC with the RNA pack-
aging signal.
MATERIALS AND METHODS
RNA sample preparation
Oligo-ribonucleotidesmatchingthesequencesofSL2,SL3and
SL4fromtheNL4-3strainofHIV-1(Figure1)werepurchased
from Dharmacon, Inc. (Lafayette, CO), deprotected according
to manufacturer’s recommendations, and extensively desalted
by ultraﬁltration on Centricon YM-3 devices (Millipore,
Bedford, MA) using a 100 mM solution of ammonium acetate
(pH 7.5). Three additional base pairs were included at the base
of the SL4 stem to stabilize its secondary structure. The purity
and integrity of each sample were conﬁrmed by ESI-FTMS
(see e.g. Figure 3a). The concentration of each stock solution
was determined by ultraviolet (UV) absorbance, using the
following molar absorptivities: 190.07 mM
 1cm
 1 for SL2,
186.55 mM
 1cm
 1 for SL3, and 201.99 mM
 1cm
 1 for
SL4. Immediately prior to use, each construct was heated to
95 C for 3 min and quickly cooled on ice to achieve proper
folding of the hairpin structures.
NC sample preparation
An expression vector containing the gene for NC (a gift from
M. F. Summers, Howard Hughes Medical Institute, Univer-
sity of Maryland, Baltimore County) was transformed and
expressed in Escherichia coli BL21(DE3)-pLysE cells. NC
was puriﬁed under non-denaturing conditions (52) and then
desalted by ultraﬁltration using 100 mM ammonium acetate
(pH 7.5), as described for the RNA samples. The purity and
integrity of the protein, including the presence of two coor-
dinated Zn
2+ ions, were conﬁrmed by ESI-FTMS, while the
sample concentration was determined by UV absorbance
(6.41 mM
 1cm
 1 molar absorptivity).
Ligand–RNA binding
All ligands used in the study were obtained from Sigma
Chemical Co. (St. Louis, MO) and utilized without further
puriﬁcation. Stock solutions were prepared by weighing each
compound and dissolving it in 100 mM ammonium acetate
(pH 7.5). Solutions containing equimolar concentrations of
up to three ligands at a time (120 mM each) were prepared
from the initial stocks to perform multiplexed binding assays.
For each step of the titration series, aliquots of RNA substrate
and multi-ligand solution were mixed together and added with
an appropriate volume of 100 mM ammonium acetate (pH 7.5)
to obtain a ﬁxed ﬁnal 0.35 mM concentration of RNA. Total
ligand concentrations ranged between 0.35 and 17.5 mMi n
subsequent steps, corresponding to a 0.1- to 5-fold excess of
total ligand. Each sample was incubated at room temperature
for 15 min to ensure that a binding equilibrium was established
in solution before ESI-FTMS analysis. Control experiments
performed with longer incubation provided no detectable
Figure 1. Sequence of the NC domain of the Gag polyprotein and secondary
structures of individual stem–loops (SL2–4) of the HIV-1 packaging signal.
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ation constants was performed in similar fashion by preparing
ﬁxed 0.35 mM solutions of RNA in the presence of 0.35–17.5
mM of eachligand in100 mM ammonium acetate (pH 7.5). The
upper boundary of ligand concentrations was generally set to
a 5-fold excess (17.5 mM) over RNA substrate after control
experiments on an unstructured oligo-deoxyribonucleotide
had shown that a 7-fold excess (24.5 mM) or more of each
drug could lead to non-speciﬁc aggregation.
NC–RNA inhibition
Complexes of NC with the different stem–loops were obtained
by mixing equimolar amounts of each component in 100 mM
ammonium acetate (pH 7.5). After 15 min at room temperat-
ure, the formation of the desired 1:1 complexes was veriﬁed
using ESI-FTMS (see e.g. Figure 7a), as described in ref. (51).
Inhibition experiments consisted of the addition of increas-
ing amounts of ligand to a ﬁxed concentration of preformed
NC-stem–loop complex. In this case, each ﬁnal solution con-
tained  3.5 mM of complex (from the initial concentrations of
NC and RNA) and 0.35–17.5 mM of inhibitor in 100 mM
ammonium acetate (pH 7.5).
Mass spectrometry
Immediately prior to analysis, analyte solutions were mixed
with a 10% volume of 2-propanol to reduce the surface tension
and facilitate the achievement of stable electrospray (47). This
addition did not have any adverse effect on the state of asso-
ciation of the non-covalent complexes investigated in this
study (51), but the dilution factor was taken in account in
subsequent calculations. Approximately 5 ml of each sample
was loaded into a nanospray needle made of uncoated boro-
silicate. A Pt-wire was inserted from the back to carry the
necessary voltage (750–1000 V). Each analysis was performed
on a Bruker Daltonics (Billerica, MA) Apex III FTMS system
equipped with a 7 T actively shielded superconducting magnet
and an Apollo thermally assisted electrospray source.
The desolvation interface was set to a temperature of 170 C.
Spectra were acquired in negative ion mode and processed
using XMASS 6.0.2 (Bruker Daltonics). A resolving power
of  150 000 was typically obtained in broadband mode. An
accuracy of  10 p.p.m. or better was achieved using a three-
point external calibration of cesium iodide.
Data analysis
Concentrations offree andboundspecies obtained upon ligand
addition were calculated from the known initial concentrations
of RNA or NC–RNA complex by using the molar fractions of
the different species in solution, which was directly determ-
ined from the intensity of the respective signals divided by
their charge state (51,53). This method relies on the reasonable
assumption that any effect induced upon binding of a small
ligand to a much larger and highly charged substrate is likely
to result in a minor shift of the overall charge state distri-
bution, rather than in complete signal suppression. Therefore,
using all the signals detected for each species divided by their
charge state can account for such a shift. In our case, the
validity of such assumption was conﬁrmed by the fact that
no signiﬁcant changes of charge distribution could be detected
during the binding experiments (see Results and Discussion).
Solution concentrations obtained from the respective molar
fractions were employed to plot binding curves and calcu-
late the respective dissociation constant (Kd) using the data-
ﬁtting algorithm included in Origin 7 (Silverdale Scientiﬁc,
Buckinghampshire, UK). All titration experiments were per-
formed at least in triplicate, thus the reported precision reﬂects
the overall uncertainty of each Kd determination.
Considering that each inhibition experiment was limited
to a maximum 5-fold ligand addition to avoid non-speciﬁc
aggregation, the ligand concentration causing 50% dissoci-
ation of initial complex (IC50) was obtained from the available
data using the isotherm curve that describes the competition of
two ligands for the same binding site:
fractional occupancy ¼
½L 
Kcomp þ½ L 
‚
where the fractional occupancy corresponds to the percent of
ligand–RNA complex determined experimentally in the pres-
ence of [L] ligand concentration, while Kcomp represents the
apparent dissociation constant of the ligand–RNA complex
under competition conditions. After subsequent increases of
ligand, the curve ﬁtted by Origin 7 was used to obtain the [L]
corresponding to a 0.5 fractional occupancy, or IC50. As indic-
ated for Kd determinations, each experiment was performed in
triplicate and Origin 7 was used to calculate the overall pre-
cision of each IC50 value.
RESULTS AND DISCUSSION
Ligands selected for the study consist of molecules represent-
ing widely different structures and binding modes with nucleic
acids (Figure 2). Many of these compounds are established
agents used in antineoplastic, antibacterial or antiviral therapy
(36–38). Grouped according to the general binding mechan-
ism, the library includes intercalators (ethidium bromide,
acridines and tetracyclines), minor groove-binders
(distamycin A, Hoechst 33258 and 33342), mixed-mode inter-
calator/minor groove-binders (mitoxantrone, daunomycin,
actinomycin D, chromomycin A3), and multifunctional
polycationic aminoglycosides (neomycin B, paromomycin
and tobramycin). The glycopeptide antibiotic vancomycin
was included as a negative control for its known activity
toward peptidoglycan units of bacterial cell walls (54,55).
Assessing ligand–RNA interactions
Speciﬁc interactions between ligands and hairpin SL2, SL3
and SL4 (Figure 1) were investigated by high-resolution mass
spectrometry to obtain the composition and stoichiometry of
ligand–RNA complexes in solution. Initially, a multiplexed
strategy was implemented to complete a rapid screening of
the binding abilities of each ligand. Different ligands were
combined in equimolar amounts to enable their simultaneous
addition to a ﬁxed amount of RNA sample (see Materials and
Methods). Multiplexing promotes competition among ligands
for the same substrate and requires sufﬁcient resolution to
unambiguously discriminate the different complexes accord-
ing to their unique molecular masses (56,57).
The principle is clearly illustrated by representative ESI-
FTMS spectra recorded upon stepwise additions of a ternary
Nucleic Acids Research, 2006, Vol. 34, No. 5 1307mixture of vancomycin, mitoxantrone and neomycin B to a
ﬁxed amount of SL2 (Figure 3, see Materials and Methods). In
the region encompassing the four charge state, the signal pro-
vided by free SL2 was readily resolvedfrom those correspond-
ing to its 1:1 complexes with mitoxantrone and neomycin B
(Figure 3b). The fact that no binding was observed for van-
comycin is consistent with its lack of activity towards nucleic
acids and excludes the possibility that non-speciﬁc aggrega-
tion might occur during sample handling or analysis. Further
additions of ternary mixture provided concentration-
dependent increases of the signals recorded for the neomycin
and mitoxantrone complexes (Figure 3c), with concomitant
decreases of those corresponding to free RNA substrate.
The pattern provided by these experiments is consistent
with the following relative scale of binding afﬁnity: neomycin
B > mitoxantrone >> vancomycin.
After initial multiplexed screening, the ligands with detect-
able binding were analyzed individually to determine the dis-
sociation constant (Kd) of their respective RNA complexes
(58–60). The fact that no signiﬁcant changes were noted in
the ESI charge states distributions upon binding is a strong
indication that the complexes’ ionization characteristics are
largely determined by the highly charged RNA components.
When this condition is veriﬁed, the signals corresponding to
Figure 2. Structures of nucleic acid-active agents incorporated in the study. Intercalators included: (a) ethidium bromide; (b) acridine; (c) tetracycline R ¼ H;
chlorotetracyclineR ¼ Cl.Mixed-modebindersincluded:(d)mitoxantrone;(e)daunomycin.Minorgroove-bindersincluded:(f)Hoechst33258R ¼ OH;Hoechst
33342R ¼ OEt;(g)distamycinA.Aminoglycosidesincluded(h)neomycinBR ¼ NH2;paromomycinR ¼ OH;(i)tobramycin.Structuresnotshownbutanalyzed
in the study: vancomycin, actinomycin D and chromomycin A3.
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responding molar fractions, which in turn can provide their
respective concentrations in solution (see Materials and
Methods) (51). The titration of each RNA substrate with
individual ligands provided characteristics binding curves
exempliﬁed in Figure 4 (see also Supplementary Data).
The Kd values obtained for the 1:1 ligand–RNA complexes
analyzed in our study are summarized in Table 1. The indi-
vidual ligands were analyzed in separate titrations to ensure
the best possible accuracy for this type of quantitative
determination and to safeguard against undesirable ligand–
ligand interactions. The initial multiplexed screening reported
very weak binding interactions for actinomycin D, which was
detected only at the highest ligand concentrations (61).
Similar results were provided by chromomycin A3, even in
the presence of Zn
2+ in a 2:1 drug to metal ratio, which
is known to stabilize its biding to double-stranded oligo-
deoxyribonucleotides (62). For this reason, individual Kd’s
were not determined for these two ligands.
Binding modes to Y-RNA stem–loops
The target RNA constructs used in our study share a common
hairpin structure including a double-stranded stem stabilized
by GC base pairs and a ﬂexible single-stranded loop formed by
four unpaired nucleotides (Figure 1). However, only SL3 pre-
sents a regular A-type helical stem (60), which enables the
observation of baseline ligand activity in the absence of more
complex structural features.
The results provided by SL3 are consistent with the char-
acteristic binding modes of the classes of nucleic acid-active
molecules included in the study. For example, the intercalators
ethidium bromide and acridine provided the lowest Kd’s in the
library, which can be explained by the strong stacking inter-
actions between their planar aromatic systems and the GC
pairs of the stem region (63,64). Consistent with the presence
of multiple putative sites, complexes including up to a
maximum of three equivalents were observed. Although
tetracyclines have been suggested to bind the hammerhead
ribozyme through an intercalating mechanism (65), only
one of their rings is actually aromatic (Figure 2) and the
fused system is not completely planar. Therefore, reduced
van der Waals stabilization is likely the cause of the low
binding afﬁnity shown by chlorotetracycline, which was the
weakest ligand in the library (Table 1).
The complexes of the antineoplastic drug mitoxantrone
(Figure 2) with B-type DNA are stabilized by a combination
of intercalation and polar interactions between its side chains
and the functional groups exposedon the minor groove surface
(66). However, SL3 presents a typical A-RNA minor groove,
which is much wider and shallower. The spacing between
polar groups does not appear to favor the side chain interac-
tions that provide additional stabilization to mitoxantrone
binding. The very weak afﬁnity manifested by other
Figure3. (a)ESI-FTMSof3.5mMSL2in100mMammoniumacetate(pH7.5)and10%volume2-propanol.Intheabsenceofligand,SL2providedanexperimental
mass of 6128.89 Da (6128.86 Da calculated from sequence). (b) ESI-FTMS of 3.5 mM SL2 in the presence of 1-fold equimolar mixture of mitoxantrone (MT),
neomycinB(NB)andvancomycin(seeMaterialsandMethods).The1:1complexMT SL2providedamassof6573.11Da(6573.06Dacalculated),whileNB SL2
provided6473.20Da (6473.17Da calculated). Unboundvancomycin wasobservedwitha massof1407.45Da (1407.43Da calculated). (c) 3.5mMSL2with 5-fold
equimolar mixture of MT, NB and vancomycin. Higher order stoichiometries were observed for MT (e.g. 2MT SL2), resulting in increments of 444.20 Da.
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(i.e. actinomycin D) (67,68) or carbohydrate nature (i.e. chro-
momycin A3) (69,70) suggests a similar mismatch with the
position of suitable functional groups on the RNA surface.
The wider and shallower minor groove of A-RNA is also at
the basis of the limited stabilization received by the minor
groove-binders distamycin A and Hoechst 33258/33342
(Figure 2) (71,72). The higher afﬁnity shown by the former
is consistent with a stronger electrostatic contribution from its
basic amidino-group (73).
Among the aminoglycoside antibiotics, neomycin B exhib-
ited the highest afﬁnity toward SL3, with a Kd slightly higher
than generic intercalators and similar to mitoxantrone
(Table 1). Paromomycin and tobramycin provided higher
Kd values, which are within range of the minor groove-
binder distamycin A. This group of drugs relies on a ﬂexible
scaffold to adapt to complex substrate structures and possesses
the ability to form multiple hydrogen bonds and electrostatic
interactions with RNA (Figure 2) (34,59,74,75). The overall
molecular architecture does not appear to be determinant in
modulating the strength of the interaction with SL3-RNA,
as suggested by the fact that paromomycin and tobramycin
include four and three carbohydrate rings, respectively, but
still bind with very similar Kd’s. On the contrary, the presence
of six amino groups in neomycin B versus ﬁve in the other two
aminoglycosides can account for the higher afﬁnity shown
by the former. This observation is consistent with a signiﬁcant
electrostatic component in the binding mechanism, which
involves strong interactions between protonated amino groups
and negative regions of the RNA substrate.
RNA structural determinants of binding activity
The Y-RNA stem–loops possess very distinctive structural
features that are expected to profoundly modify the binding
modes manifested by small ligands. Each single-stranded loop
presents a different base composition and can assume variably
ﬂexible conformations stabilized by limited stacking and
hydrogen bonds (76–78). This ﬂexibility facilitates protein
binding and possibly RNA–RNA tertiary interactions with
other regions of the 50-UTR. However, in the context of isol-
ated hairpin constructs, this characteristic does not facilitate
the formation of well-deﬁned sites or stable pockets for the
speciﬁc binding of small ligands. On the contrary, the double-
stranded stems present relatively stable motifs that could serve
as potential binding sites. In particular, the AUA triple base
platform of SL2 and the tandem GU wobbles of SL4 provide
far greater opportunities for speciﬁc interactions than the
SL3’s uninterrupted helical structure.
Figure 4. Ligand–SL2bindingcurves.Forthesakeofclarity,onlyonerepresentativecurveisshownforeachclassofligands:neomycinB(filledsquare),ethidium
bromide (filled circle), mitoxantrone (filled triangle), distamycin A (filled star) and chlorotetracycline (filled diamond). See Materials and Methods for conditions.
See Supplementary Data for ligand–SL3 and ligand–SL4 binding curves.
Table 1. Summary of dissociation constants (Kd’s) determined for stem–loop
complexes with individual ligands
Ligand SL2 SL3 SL4
Neomycin B 3.0 ± 0.6 4.2 ± 0.3 1.0 ± 0.2
Paromomycin 8.8 ± 1.1 37.7 ± 1.3 8.0 ± 1.1
Tobramycin 9.7 ± 1.6 38.7 ± 3.7 7.8 ± 1.1
Ethidium Bromide 2.6 ± 0.2 1.9 ± 0.2 12.7 ± 1.6
Acridine 2.8 ± 0.3 2.4 ± 0.3 12.7 ± 1.4
Mitoxantrone 6.6 ± 0.7 3.9 ± 0.5 10.0 ± 0.7
Daunomycin 22.7 ± 3.6 8.2 ± 0.9 12.1 ± 0.9
Distamycin A 75.4 ± 7.5 28.5 ± 4.7 57.9 ± 3.5
Hoechst 33342 99.9 ± 12.5 88.2 ± 6.6 170.6 ± 17.9
Chlorotetracycline 161.1 ± 14.8 883.5 ± 299.6 391.0 ± 81.1
All values of Kd are expressed in mM units. In preliminary multiplexed screen-
ing, Hoechst 33258 and tetracycline displayed very similar binding activities
to Hoechst 33342 and chlorotetracycline, respectively, thus these ligands were
not subjected to individual titrations.
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the stem–loop create a kink that enables the nucleobase of U14
to become approximately co-planar with those of A5 and A15
to complete a triple base structure (78). The platform motif
causes a shift of the helical axis in the midsection of the
stem and subjects the minor groove to signiﬁcant opening
(Figure 5a). This situation causes subtle changes in the normal
base-stacking pattern, which result in a noticeable decrease of
afﬁnity for intercalating molecules (Table 1). The dimensions
and surface of the minor groove are distorted to a degree that
makes this region even less favorable to minor groove-binders.
This is consistent with the greatly reduced afﬁnity of
distamycin A and Hoechst 33258/33342 toward SL2 than
toward SL3. On the contrary, the afﬁnity for SL2 displayed
by the aminoglycosides was signiﬁcantly higher. Considering
the electrostatic character of aminoglycoside binding, this
increase suggests the possible interaction with a highly neg-
ative region created by the closeproximityof the O6of G1,G2
and G17 in the major groove below the AUA platform
(Figure 5a and b). Competition experiments aimed at compar-
ing the binding activity of wild-type SL2 with a mutant in
which the platform was eliminated by deletion of A15 showed
a 50% reduction inaminoglycoside afﬁnities (see Supplement-
ary Data), thus supporting the role played by this structure
in ligand binding. Selective gas-phase fragmentation of the
neomycin–SL2 complex has recently provided further con-
ﬁrmation of the putative binding site (79).
The structure of SL4 includes contiguous GU pairs (tandem
wobbles, Figure 1), which involve non-canonical base pair-
ing interactions. This arrangement forces the double-stranded
stem to assume a wider and less compact conformation,
which causes a discontinuity in the stacking pattern and
reduces its stability to thermal denaturation (77). These effects
contribute to the inferior binding of intercalators to this
substrate as compared to both SL3 and SL2. The decreased
afﬁnity experienced by mitoxantrone was not as prominent
becauseof its preference for GCbasepairs(66).This observation
points towards sites located away from the tandem wobbles and
closer to the loop or the base of the stem (Figure 1). The wider
dimensions of the minor groove greatly affected the Kd of
groove-binders, but the large electrostatic component in the dis-
tamycin mechanism limited its afﬁnity loss (Table 1).
The functional groups exposed on the surface of the tandem
wobbles combine to provide an ideal situation for binding the
aminoglycosidic antibiotics. In fact, the major groove presents
a highly negative region (Figure 6a and b), which is created
by placing the G-N7, G-O6 and U-O4 of each wobble on the
same plane and in close proximity to each other (80). Delim-
ited by the amino groups of the GC pairs above and below the
wobbles, this area constitutes an excellent binding site for
positively charged aminoglycosides, which in fact offered
the lowest Kd’s of the library. This hypothesis was tested
using competitive binding experiments that included a mutant
SL4m in which G5 and G15 were substituted by A to eliminate
the tandem wobbles and obtain a double-stranded stem similar
tothatofSL3 (seeSupplementaryData). TheobservedSL4>>
SL4m   SL3 relative binding scale is consistent with the
strong stabilizing effects of the wobble structure on the
aminoglycosides interactions. The location of this binding
site was further supported by gas-phase fragmentation
experiments (79).
Inhibition of NC binding activity
The effects of ligands on the speciﬁc binding of NC protein to
the Y-RNA substrates were investigated in vitro by adding
increasing amounts of ligand to preformed NC-hairpin com-
plex (see Materials and Methods). Using experimental condi-
tions optimized earlier to determine the stoichiometry and
dissociation constants of these protein–RNA assemblies
(51), ESI-FTMS was applied to characterize the species pre-
sent in solution upon addition of ligand and reveal the fate of
the protein–RNA complex. As exempliﬁed in Figure 7 and
summarized in Table 2, at least three different outcomes
were realized: (i) no detectable effects; (ii) dissociation of
the protein–RNA complex; (iii) binding of ligand to the
Figure 5. (a) SL2 electrostatic surface (PDB:1ESY) calculated for a 100 mM
salt environment utilizing Delphi (85) and visualized in Pymol (86). The red
coloring marks highly electronegative regions, such as the phosphates and the
major groove below the AUA triple base platform. (b) The bases forming the
AUAplatformarecoloredinorange,whiletheO6ofG1,G2andG17liningthe
electronegative pocket are highlighted in red.
Figure 6. (a) SL4 electrostatic surface (PDB: 1JTW) calculated in a 100 mM
salt environment utilizing Delphi (85) and visualized in Pymol (86). The red
area indicated by the arrow corresponds to a negatively charged surface in the
majorgrooveofthetandemGUwobbles.(b)Highlightedinred,theN7andO6
ofG5andG15formthiselectronegativeregion,togetherwiththeO4ofU6and
U16. The base pairs flanking the wobbles are colored in orange.
Nucleic Acids Research, 2006, Vol. 34, No. 5 1311complex with formation of a ternary species. In the case of
NC SL3, for example, the minor groove-binder Hoechst
33342 did not affect the stability of the complex, yielding
results identical to those obtained for control samples in the
absence of ligand (Figure 7a). Neomycin B induced a
concentration-dependent decrease of the NC SL3 signal and
a concomitant increase of the corresponding ligand–SL3 sig-
nal, which is consistent with the dissociation of the initial
protein–RNA complex (Figure 7b). On the contrary, ternary
species were observed for mitoxantrone, which exhibited up to
threeequivalentsboundtothecomplexandnodetectablesigns
of dissociation (Figure 7c).
A close look at the available high-resolution structures is
necessary to rationalize the results of ligand interference. In
the NC SL3 complex, the N-terminal tail of NC folds into a
310 helix that makes contact with the stem’s major groove
(Figure 8a) (52). Partial obstruction of the upper stem should
explain why intercalators and mixed-mode binders provided
the same stoichiometries with NC SL3 as with free SL3, but
noticeably lower afﬁnities. Indeed, the binding sites in the
upper stem are still accessible from the minor groove side,
or during the off-phase of the protein–RNA binding equilib-
rium, while those in the lower stem remain unhindered by NC.
Similarly, a completely unobstructed minor groove enables
the binding of the strongest groove-binder, distamycin A,
which provided a detectable ternary species.
The ability of aminoglycosides to displace NC and form
ligand–SL3 complexes is consistent with at least partially
overlapping binding sites on the RNA substrate. In fact, the
N-terminal zinc-ﬁnger is involved in electrostatic interactions
with the major groove of the hairpin upper stem (Figure 8a),
which could be alternatively occupied by the aminoglycoside.
Further support for competing binding equilibria is provided
by the observation that a certain accumulation of drug was
necessary in solution before dissociation became apparent.
For instance, a 5-fold excess of neomycin B over the initial
concentration of NC SL3 was necessary to obtain  30%
complex dissociation. An overall IC50 of 30.1 ± 2.8 mM
was determined for this aminoglycoside (Table 2, see
Materials and Methods). It is interesting to note that the
other aminoglycosides provided a trend supporting the
conclusion that the tightest RNA binder in the series is also
the best NC inhibitor.
The complex of NC with SL2 involves interactions between
the zinc-ﬁngers and nucleobases exposed on the hairpin
tetraloop, in analogy to the SL3 complex (81). In this case,
however the310 helixispackedagainstthe N-terminalknuckle
and binds to the minor groove of the AUA platform for fur-
ther stabilization (Figure 8b). The stem’s upper section is still
accessible by intercalators and mixed-mode binders from the
major groove side, while the lower section is unhindered by
Figure 7. (a) ESI-FTMS of 3.5 mMN C  SL3 in 100 mM ammonium acetate (pH 7.5) and 10% volume 2-propanol. In the absence of ligand, NC SL3 provided an
experimental mass of 12 946.90 Da (12 946.94 Da calculated from the respective sequences, including two Zn
2+ ions). (b) 5-fold addition of neomycin B (NB)
induced dissociation of NC SL3 and formation of NB SL3 with an observed mass of 7072.20 Da (7072.23 Da calculated). (c) A ternary species NC SL3·MT was
observedwithamassof13391.14Da(13391.03Dacalculated)upon5-foldadditionofmitoxantrone(MT)underthesameconditions.Higherorderstoichiometries
were also observed with 444.20 Da increments.
Table 2. Summary of ligand effects on NC-hairpin complexes
Ligand NC SL2 NC SL3 NC SL4
Neomycin B 1.9 ± 0.3
a 31.1 ± 2.8
b 2.9 ± 0.2
b
Paromomycin 9.3 ± 1.9
a 311.1 ± 13.3
b 17.8 ± 1.2
b
Tobramycin 10.8 ± 1.7
a 321.0 ±14.5
b 17.6 ± 1.3
b
Ethidium Bromide 13.5 ± 0.6
a 6.4 ± 0.9
a 25.5 ± 2.3
a
Acridine 17.1 ± 0.4
a 14.5 ± 1.2
a 46.1 ± 3.4
a
Mitoxantrone 11.9 ± 1.8
a 10.3 ± 1.8
a 6.9 ± 5.9
a
Daunomycin 44.7 ± 4.0
a 29.8 ± 1.9
a 13.1 ± 2.1
a
Distamycin A No Effect 58.1 ± 6.3
a No Effect
Hoechst 33342 No Effect No Effect No Effect
Chlorotetracycline No Effect No Effect No Effect
aDissociation constant (Kd) calculated for ternary NC-hairpin–ligand com-
plexes with 1:1:1 stoichiometry.
bConcentration at which 50% of initial NC-hairpin complex was dissociated
(IC50) (see Materials and Methods). Values of Kd and IC50 are expressed in
mM units.
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NC SL2 with the same stoichiometries observed for free SL2,
but weaker overall afﬁnities. The fact that the weak interac-
tions of minor groove-binders were absent in NC SL2 sug-
gests that these ligands may share a binding site with the
protein in the minor groove of the upper stem, which is
obstructed by the 310 helix. On the contrary, the presence
of a common site is not likely for aminoglycosides, which
failed to induce inhibition and instead produced ternary com-
plexes with the same stoichiometries observed for free SL2.
These results point towards a possible binding site placed in a
relatively wide electronegative area below the triple base plat-
form. This region is located on the major groove side of the
stem and is therefore unobstructed by the 310 helix (Figure 8b).
Interpreting the results obtained for NC SL4 is made more
difﬁcult by the absence of a high-resolution structure. Extens-
ive chemical probing of the complex has shown that accessible
nucleobases in the loop and tandem wobbles become inert to
footprinting agents in the presence of NC, in analogy to the
other stem–loops (82). However, it has been suggested that
the more compact structure of this tetraloop may be less con-
ducive to protein–RNA interactions, while greater contribu-
tions from the upper stem and tandem wobbles are expected to
offer stabilization (77,83). In this context, ligand interference
can actually provide precious information on the possible spa-
tial arrangement of the NC SL4 complex. In fact, the inhib-
itory effects of aminoglycosidic antibiotics indicate a clear
competition between ligand and NC for the same region of
the RNA structure. As discussed earlier, the putative binding
site for aminoglycosides corresponds to a highly electroneg-
ative area in the major groove of the tandem wobbles.
The same site is certainly capable of effective interactions
with the basic N-terminal helix of NC, in agreement with
an increased role of the wobbles in stabilizing protein binding.
Therefore, all the available information suggests many
similarities between the situation of NC SL4 and NC SL3,
which may still involve weaker contacts of the zinc-ﬁngers
with the tetraloop and upper stem, while the 310 helix could
reach down to interact with the wobbles in the major groove.
As observed for NC SL3, the values of IC50 for the addition
of aminoglycosides to NC SL4 follow the same trend shown
by the Kd’s of the correspondent ligand–SL4 complexes
(Table 2). In agreement with a competitive binding mechan-
ism, the tightest RNA binder was also found to be the best
inhibitor. The much lower IC50’s obtained for NC SL4 than
for NC SL3 can be explained by a combination of at least two
factors. The ﬁrst is the much weaker afﬁnity of NC for SL4
than for SL3, as shown by Kd values of 1.3 ± 0.5 mM and
178 ± 64 nM for the respective NC complexes (51). The
second is the stronger afﬁnity exhibited by the aminoglycos-
ides for free SL4 than for free SL3 (Table 1).
Finally, the lack of effects from minor groove-binders can
be attributed to their already weak afﬁnity for free SL4, as well
as to possible site overlap. Ideally, minor groove-binders are
designed to achieve optimal binding within the deep and nar-
row groove of B-type DNA (71,72,84). However, in addition
to having much wider and shallower dimensions in A-type
RNA, the minor groove is further widened in SL4 by the
non-canonic pairing of the tandem wobbles. It is conceivable
that weak ligand interactions may occur on both the minor and
major grooves of this stem–loop, which would explain the
observed competition with NC. Considering the behavior of
the otherNC-hairpincomplexes,it was notsurprising toobtain
ternary species with general intercalators and mixed-mode
binders, which provided similar stoichiometries and weaker
afﬁnities than with free SL4.
CONCLUSIONS
These results show for the ﬁrst time that aminoglycosidic
antibiotics are capable of disrupting the speciﬁc binding of
NC to SL3 and SL4 in vitro. The role of NC–SL3 interactions
in genome recognition and packaging offers the intriguing
possibility of employing aminoglycoside analogues to inter-
fere with genome recognition and encapsidation. However,
mutagenesis studies have indicated that other 50-UTR struc-
tures contribute to a different extent to the encapsidation pro-
cess (18,30), thus inhibition of NC–SL3 interactions alone
may not completely stop the production of properly packaged
virions. The signiﬁcance of the inhibition of NC–SL4 inter-
actions in vitro cannot be evaluated without more informa-
tion about the role played by the SL4 sequence in stabilizing
alternative 50-UTR conformers through long distance base
pairing interactions (40,41). In this direction, future studies
will address the hypothesis that the NC-mediated transition
between 50-UTR conformers may involve the binding to a
transient hairpin structure, which in this case could provide
a favorable target for aminoglycosides activity.
Finally, these results are also emblematic of the many chal-
lenges facing the development of small drug ligands to inter-
fere with the interactions of NC with 50-UTR. The systematic
evaluation of archetypical nucleic acid ligands has shown
that the ability to bind target RNA stem–loops does not neces-
sarilycorrelate withactualdisruptionofNC-hairpincomplexes.
The range of effects observed for the different ligands is a clear
Figure 8. High-resolution structures of (a)N C  SL3 (PDB:1A1T) and (b)
NC SL2 (PDB:1F6U). The AUA triple base platform is highlighted in orange.
The arrows point to the putative binding sites for aminoglycosidic antibiotics.
Nucleic Acids Research, 2006, Vol. 34, No. 5 1313indication that inhibitory activity is achievable by carefully
matching the speciﬁc structural features of the target with
the characteristics of the ligand. Therefore, greater efforts
will be required to identify the most effective target among
the many complexes formed by NC with 50-UTR structures,
or to develop broader spectrum ligands capable of simultan-
eously attacking multiple suboptimal targets.
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